BTIG Research Has Lowered Expectations for Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) had its price target lowered by analysts at BTIG Research from $11.00 to $9.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. BTIG Research’s target price would indicate a potential upside of 368.75% from the stock’s previous […]

Leave a Reply

Your email address will not be published.

Previous post Hagerty (NYSE:HGTY) Sets New 1-Year Low Following Insider Selling
Next post Head-To-Head Review: Smith Douglas Homes (SDHC) & The Competition